Stay updated with breaking news from Olympia Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
STRICTLY EMBARGOED UNTIL Tuesday 6 September 2022 00:01 BST LYNPARZA (olaparib) APPROVED IN GREAT BRITAIN AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER First and only approved medicine in Great Britain which targets germline BRCA mutations in pati...
Breast cancer is the most diagnosed cancer worldwide with an estimated 2.3 million patients diagnosed in 2020.
Testing will be reimbursed for patients with early-stage breast cancer to guide adjuvant treatment with the PARP inhibitor Lynparza.
SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer